European Commission Approves Erbitux® (cetuximab) in Combination with Encorafenib and FOLFOX for First-Line Treatment of Metastatic Colorectal Cancer with BRAF V600E Mutation
ERBITUX in combination with encorafenib and FOLFOX is the first and only approved targeted regimen for the first-line treatment of adult patients with BRAF V600E-mutant mCRC The approval is based on the pivotal Phase 3 BREAKWATER trial, which demonstrated statistically significant and clinically meaningful improvements in both progression-free survival (PFS)






